In­dia of­fers in­cen­tives to do­mes­tic drug­mak­ers for APIs; Af­ter PhI­II tri­als, Tai­ho li­cens­es Arokaris in Japan

In­dia has been de­pen­dent on the im­port of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents to man­u­fac­ture its drugs. But thanks to a a re­cent gov­ern­ment ini­tia­tive, 35 of those will now be man­u­fac­tured in the coun­try.

In­dia de­pends on im­ports for 90% of its APIs, Man­sukh Man­daviya, the Min­is­ter of Health & Fam­i­ly Wel­fare and Chem­i­cals and Fer­til­iz­ers told re­porters this week. But thanks to a pro­duc­tion-linked in­cen­tive scheme brought on by the gov­ern­ment, in-coun­try phar­mas can re­ceive pay­ments over the next six years for mak­ing for­mu­la­tions, bio­phar­ma­ceu­ti­cals, ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, key start­ing ma­te­r­i­al, drug in­ter­me­di­ates, and in vit­ro di­ag­nos­tic med­ical de­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER